Abstract

Treatment of differentiated thyroid cancer (DTC) most often involves a combination of surgery, radioactive iodine (RAI) and suppression of thyroid-stimulating hormone (TSH). In specific situations, external beam radiotherapy (EBRT) could be of benefit, although this remains controversial because of a lack of randomized evidence to support its use. In contrast, EBRT is of standard use in the multimodal management of anaplastic thyroid cancer (ATC) with surgery and systemic agents. Despite this, outcomes remain poor, supporting the need for additional research of this devastating disease. This chapter focuses on the role of EBRT in DTC and ATC.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.